Travis J Hollmann
Overview
Explore the profile of Travis J Hollmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
76
Citations
4977
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Aleynick N, Li Y, Xie Y, Zhang M, Posner A, Roshal L, et al.
Sci Data
. 2023 Apr;
10(1):193.
PMID: 37029126
Defining cellular and subcellular structures in images, referred to as cell segmentation, is an outstanding obstacle to scalable single-cell analysis of multiplex imaging data. While advances in machine learning-based segmentation...
12.
Pourmaleki M, Socci N, Hollmann T, Mellinghoff I
Cancer Discov
. 2023 Apr;
13(4):824-828.
PMID: 37009699
The shift in cancer therapy from broadly cytotoxic agents toward "personalized" treatments that target specific alterations in each patient's tumor requires diagnostic pathology approaches that are quantitative and biospecimen-friendly. Novel...
13.
Hirschhorn D, Budhu S, Kraehenbuehl L, Gigoux M, Schroder D, Chow A, et al.
Cell
. 2023 Mar;
186(7):1432-1447.e17.
PMID: 37001503
Cancer immunotherapies, including adoptive T cell transfer, can be ineffective because tumors evolve to display antigen-loss-variant clones. Therapies that activate multiple branches of the immune system may eliminate escape variants....
14.
Vazquez-Garcia I, Uhlitz F, Ceglia N, Lim J, Wu M, Mohibullah N, et al.
Nature
. 2022 Dec;
612(7941):778-786.
PMID: 36517593
High-grade serous ovarian cancer (HGSOC) is an archetypal cancer of genomic instability patterned by distinct mutational processes, tumour heterogeneity and intraperitoneal spread. Immunotherapies have had limited efficacy in HGSOC, highlighting...
15.
Ghahremani P, Li Y, Kaufman A, Vanguri R, Greenwald N, Angelo M, et al.
Nat Mach Intell
. 2022 Sep;
4(4):401-412.
PMID: 36118303
Reporting biomarkers assessed by routine immunohistochemical (IHC) staining of tissue is broadly used in diagnostic pathology laboratories for patient care. To date, clinical reporting is predominantly qualitative or semi-quantitative. By...
16.
Vanguri R, Luo J, Aukerman A, Egger J, Fong C, Horvat N, et al.
Nat Cancer
. 2022 Aug;
3(10):1151-1164.
PMID: 36038778
Immunotherapy is used to treat almost all patients with advanced non-small cell lung cancer (NSCLC); however, identifying robust predictive biomarkers remains challenging. Here we show the predictive capacity of integrating...
17.
Padron L, Maurer D, OHara M, OReilly E, Wolff R, Wainberg Z, et al.
Nat Med
. 2022 Jun;
28(6):1167-1177.
PMID: 35662283
Chemotherapy combined with immunotherapy has improved the treatment of certain solid tumors, but effective regimens remain elusive for pancreatic ductal adenocarcinoma (PDAC). We conducted a randomized phase 2 trial evaluating...
18.
Vanguri R, Fenn K, Kearney M, Wang Q, Guo H, Marks D, et al.
Clin Breast Cancer
. 2022 May;
22(6):538-546.
PMID: 35610143
Background: Pathologic response at the time of surgery after neoadjuvant therapy for HER2 positive early breast cancer impacts both prognosis and subsequent adjuvant therapy. Comprehensive descriptions of the tumor microenvironment...
19.
Sia T, Manning-Geist B, Gordhandas S, Murali R, Marra A, Liu Y, et al.
Int J Gynecol Cancer
. 2022 May;
32(8):1017-1024.
PMID: 35545291
Background: Although immune checkpoint blockade has demonstrated limited effectiveness against ovarian cancer, subset analyses from completed trials suggest possible superior efficacy in the clear cell carcinoma subtype. Objective: To describe...
20.
Kuo A, Hassoun H, Shah U, Gordon A, Hollmann T, Landau H, et al.
Leuk Lymphoma
. 2022 May;
63(9):2233-2237.
PMID: 35532206
No abstract available.